
Data gaps in aging biomarkers
Marton Meszaros proposes studies linking repeated biological samples to health outcomes, testing how meals and illness affect biomarkers, and checking whether treatment-related changes predict benefits to patients.

The longevity field must grow to deliver more than a trickle of healthy years. Norn runs programs guiding undergraduates and foreign talent to work on longevity, and connects exceptional people to work together on the most important bottlenecks.
Industrializing longevity means turning one-off discoveries into a repeatable pipeline, and that pipeline runs on great people taking on critical work.
Today, people find their way to the longevity field from chance encounters or an early sense of purpose, rather than through institutions and public role models. Thus the field remains smaller than it should be.
Our talent programs aim to change that. We reach undergraduates who haven’t thought of aging as something they could work on, help strong researchers outside the U.S. move to where the work happens, and connect talented people to the field’s real work.
Student Clubs for Advancing the Longevity Ecosystem (SCALE) funds student-led groups, so students see serious opportunities in longevity as they define their direction in life. This program is a collaboration with Second Century Foundation (SCF).
Funded groups expose students to high-quality aging research, using the funding for club operations and for activities like public symposia and workshops, dinners with professors and speakers.
Group leaders also get access to a resource hub, mentorship from Norn and SCF, and introductions to researchers, founders, funders and leaders of other clubs. Leaders may be invited to join Norn Group’s Longevity Nexus.
Undergraduate-led aging and longevity groups, new or established, primarily in the U.S., Canada and Europe. Groups do not have to be official university-affiliated clubs, and students without a group can apply to start one. Graduate students can be members, but undergraduates must lead.
Annual grants to start or run a group, including its events. The amount, and whether we renew, depends on a year-end update on the group’s impact, progress and plans for the next year.
A core team of ~2-5 students with one designated leader, who are serious about aging. Groups should meet in person and focus on aging biology and disease, drug development, and/or projects advancing the longevity field. General biotech or biology groups don’t qualify, and neither do groups built around wellness or biohacking.
We review applications on a rolling basis and reply to everyone within three weeks. Shortlisted leaders have a call with reviewers from Norn Group and/or Second Century Foundation. A recommendation or direct referral from someone we trust can speed up review.
Longevity Nexus brings the field’s most driven researchers, founders and builders together, so their ideas get tested hard and turn into projects and companies.
Members bring expertise in biology, biotechnology and drug development to weekly deep dives. They give each other feedback, bring in outside experts and take on projects, and the best of that work becomes public resources for the field, like the examples below.
From time to time, members get opportunities to work on new research projects, companies and other longevity efforts, with mentorship from Martin Borch Jensen.
People actively doing serious work that will improve the longevity field, in research, companies or elsewhere. Members don’t have to be scientists. See the range of current members on the People page.
Attend at least 40% of weekly sessions on longevity and contribute work regularly. Members must host at least one session every four months. Let us know if you need to step away or cannot meet the minimum attendance.
Weekly sessions are virtual, with collaboration continuing on Slack and occasional in-person meet-ups in San Francisco and Boston. There are no citizenship requirements.
You can apply at any time. We review applications irregularly and only reply to the applicants we select. To strengthen an application, share serious work that advances longevity or ask a Norn Group or Nexus member you know to recommend you. A recommendation from someone we trust speeds up the review.
Gene therapy can act on targets conventional drugs cannot. We assess what it would take to make these treatments safe and affordable for common diseases.
Mouse lifespan studies take years. We propose an independent program to test whether aging clocks can predict treatment effects on lifespan before those studies finish.
A proposal for testing aging drugs against multiple diseases in one trial, with tools to assess its statistical and economic feasibility.
Choosing the right disease to target can make or break a longevity drug program. We compare 47 age-related diseases to guide you towards a viable path to patients.